Hilal Gul-Uludag
Overview
Explore the profile of Hilal Gul-Uludag including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Landry B, Gul-Uludag H, Plianwong S, Kucharski C, Zak Z, Parmar M, et al.
J Control Release
. 2016 Jan;
224:8-21.
PMID: 26742943
In spite of high complete remission rates in Acute Myeloid Leukemia (AML), little progress has been made in the long-term survival of relapsing AML patients, urging for the development of...
2.
Landry B, Valencia-Serna J, Gul-Uludag H, Jiang X, Janowska-Wieczorek A, Brandwein J, et al.
Mol Ther Nucleic Acids
. 2015 May;
4:e240.
PMID: 25965550
Leukemias arise from genetic alterations in normal hematopoietic stem or progenitor cells, leading to impaired regulation of proliferation, differentiation, apoptosis, and survival of the transformed cells. With the advent of...
3.
Gul-Uludag H, Valencia-Serna J, Kucharski C, Marquez-Curtis L, Jiang X, Larratt L, et al.
Leuk Res
. 2014 Sep;
38(11):1299-308.
PMID: 25262448
The adhesion receptor CD44 plays an important role in the survival and retention of leukemic stem/progenitor cells (LSPC) within the bone marrow (BM) niche, as well as in the high...
4.
Sahin B, Fife J, Parmar M, Valencia-Serna J, Gul-Uludag H, Jiang X, et al.
Biomaterials
. 2014 Aug;
35(34):9382-94.
PMID: 25128374
Cutaneous T-cell lymphomas (CTCLs) arise from specific molecular aberrations that lead to uncontrolled cell proliferation. RNA interference (RNAi) with short interfering RNAs (siRNAs) is a feasible approach to interrupt aberrant...
5.
Valencia-Serna J, Gul-Uludag H, Mahdipoor P, Jiang X, Uludag H
J Control Release
. 2013 Jun;
172(2):495-503.
PMID: 23726887
RNAi represents a new alternative for treatment of chronic myeloid leukemia (CML) to overcome the difficulties of current drug treatments such as the acquired resistance. However, potent carriers that can...
6.
Marquez-Curtis L, Gul-Uludag H, Xu P, Chen J, Janowska-Wieczorek A
Cytotherapy
. 2013 Apr;
15(7):840-9.
PMID: 23623275
Background Aims: The interaction between stromal cell-derived factor (SDF)-1 and its receptor CXCR4 is one of the mechanisms by which mesenchymal stromal cells (MSCs) are recruited to sites of injury....
7.
Landry B, Montazeri Aliabadi H, Samuel A, Gul-Uludag H, Jiang X, Kutsch O, et al.
PLoS One
. 2012 Sep;
7(8):e44197.
PMID: 22952927
Use of small interfering RNA (siRNA) is a promising approach for AML treatment as the siRNA molecule can be designed to specifically target proteins that contribute to aberrant cell proliferation...
8.
Xu P, Gul-Uludag H, Ang W, Yang X, Huang M, Marquez-Curtis L, et al.
Biotechnol Lett
. 2012 Jul;
34(10):1965-73.
PMID: 22763849
Low-intensity pulsed ultrasound (LIPUS) stimulated the viability, proliferation and differentiation of hematopoietic stem/progenitor cells (HSPC) from fresh and cryopreserved peripheral blood leukapheresis product, as well as cord blood when applied...
9.
Gul-Uludag H, Lu W, Xu P, Xing J, Chen J
Biotechnol Lett
. 2012 Jan;
34(5):989-93.
PMID: 22286181
Monocyte-based gene therapies in cancer have been hampered by either the resistance of these cells to non-viral molecular delivery methods or their poor trafficking to the tumor site after their...
10.
Gul-Uludag H, Xu P, Marquez-Curtis L, Xing J, Janowska-Wieczorek A, Chen J
Stem Cells Dev
. 2011 Nov;
21(10):1587-96.
PMID: 22047530
The chemokine stromal cell-derived factor (SDF)-1α/CXCL12 and its receptor CXC chemokine receptor 4 (CXCR4) play a crucial role in the homing/engraftment and retention of hematopoietic stem/progenitor cells (HSPCs) in the...